The results of a recent randomized controlled phase 2 trial of HCQ in 35 patients with various forms of interstitial lung disease (caused by the pathogenic variants of SFTPC, ABCA3, NKX2.1, TBX4, COPA, etc.)did not identify an overall HCQ treatment effect (23). Here, NKX2-1 is linked to interstitial lung disease.